Subscribe To
XBIO / VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.
Read More
Content Topics
Volitionrx
Limited
Inks
Collaboration
Deals
With
Xenetic
Biosciences
Salarius
Pharmaceuticals
Develop
Cancer
Treatments
Stock
XBIO
Posted: Aug 2 2022, 10:07
Author Name: Proactive Investors
Views: 112513
XBIO News
By Proactive Investors
August 2, 2022
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to more_horizontal